Trial Profile
An Open Label, Randomized, Multiple-Dose, Parallel Study to Evaluate Efficacy and Safety of Intravenous Infusion of Nanosomal Paclitaxel Lipid Suspension (Intas Pharmaceuticals Ltd.) and Taxol® (Paclitaxel Injection Concentrate, Bristol-Myers Squibb.) in Metastatic Breast Cancer Patients after failure of prior chemotherapy
Status:
Completed
Phase of Trial:
Phase II/III
Latest Information Update: 05 Nov 2022
Price :
$35
*
At a glance
- Drugs Paclitaxel (Primary)
- Indications Advanced breast cancer
- Focus Therapeutic Use
- 13 Sep 2022 Results (n=174) presented at the 47th European Society for Medical Oncology Congress
- 30 May 2014 Primary endpoint 'Objective-clinical-response-rate' has been met.
- 30 May 2014 Results presented at the 50th Annual Meeting of the American Society of Clinical Oncology.